• HOME
  •  > 
  • 臨床医学：外科
  •  > 
  • 雑誌
  •  >  脳神経外科速報　2020年増刊号　悪性脳腫瘍のすべて ―Neuro-Oncologyの教科書―

脳神経外科速報　2020年増刊号　悪性脳腫瘍のすべて ―Neuro-Oncologyの教科書―

出版社： メディカ出版
発行日： 2020-10-01
分野： 臨床医学：外科  >  雑誌
ISSN： 09171495
雑誌名：
特集： 悪性脳腫瘍のすべて ―Neuro-Oncologyの教科書―
電子書籍版： 2020-10-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

目次

  • 特集　悪性脳腫瘍のすべて ―Neuro-Oncologyの教科書―
    　　　遺伝子診断時代の臨床リアルワールド

    【I章 総論】
    ◆1 悪性脳腫瘍治療に必要な分子標的療法の理解のために

    【II章 遺伝子異常】
    ◆1 グリオーマにおける遺伝子異常
    ◆2 小児脳腫瘍における遺伝子異常

    【III章 画像診断】
    ◆1 画像診断（MRI）
    ◆2 画像診断（CTとPET）

    【IV章 病理診断（分子診断）】
    ◆1 成人グリオーマの分子分類
    ◆2 小児脳腫瘍の分子分類

    【V章 手術】
    ◆1 膠芽腫（GBM）の手術 ─ 我々の流儀1：側頭葉内側膠芽腫を中心に
    ◆2 膠芽腫（GBM）の手術 ─ 我々の流儀2：迅速な術前準備と安全・確実な腫瘍摘出
    ◆3 膠芽腫（GBM）の手術 ─ 我々の流儀3：分子遺伝学的機序に基づくグリオーマの治療戦略
    ◆4 膠芽腫（GBM）の手術 ─ カルムスチンを用いた治療
    ◆5 Lower grade glioma の手術 ─ 我々の流儀1：個別性を考慮した最善の治療法の選択
    ◆6 Lower grade glioma の手術 ─ 我々の流儀2：予後と摘出
    ◆7 Lower grade glioma の手術 ─ 我々の流儀3：maximal safe resection を目指して
    ◆8 Insular glioma の手術
    ◆9 覚醒下手術（Awake surgery）
    ◆10 脳室内腫瘍の手術
    ◆11 中枢神経系原発悪性リンパ腫の手術 ─ 鑑別診断と生検の重要性
    ◆12 胚細胞腫瘍（germ cell tumor）の手術
    ◆13 髄芽腫の手術
    ◆14 転移性脳腫瘍の手術

    【VI章 補助療法】
    ◆1 放射線治療
    ◆2 ホウ素中性子捕捉療法（BNCT）
    ◆3 陽子線治療
    ◆4 化学療法1（グリオーマ）
    ◆5 化学療法2（中枢神経系胚細胞腫瘍）
    ◆6 化学療法3（中枢神経系原発悪性リンパ腫）
    ◆7 化学療法4（転移性脳腫瘍）
    ◆8 膠芽腫に対する新しい治療法 ─ オプチューン(R)（NovoTTF-A100）
    ◆9 悪性神経膠腫に対するワクチン療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 総論

P.20 掲載の参考文献
1) テモダール(R) 添付文書
 
2) 甲斐寛倫 : "分子標的概論", 62-70 (日本がん治療認定医機構 教育委員会監修 : がん治療認定医教育セミナーテキスト 第13版, 日本がん治療認定医機構, 東京, 2019)
 
3) 土原一哉 : "がんの生物学・分子生物学", 1-7 (日本がん治療認定医機構 教育委員会監修 : がん治療認定医教育セミナーテキスト 第13版, 日本がん治療認定医機構, 東京, 2019)
 
4) 竹島浩, 柿澤昌 : "細胞間情報伝達", 37-46 (竹島浩, 柿澤昌編集 : 基礎生命科学 第2版, 京都廣川書店, 京都, 2013)
 
5) 西田栄三 : "シグナル伝達酵素とそのアロステリックな制御", 43-87 (西田英三 : 細胞のシグナル伝達, メディカルインターナショナル, 東京, 2016)
 
6) Taylor MD, Northcott PA, Korshunov A, et al : Molecular subgroups of medulloblastoma : the current consensus. Acta Neuropathol 123 : 465-72, 2012
PubMed
7) 西田栄三 : "シグナル伝達における翻訳後修飾の役割", 89-118 (西田英三 : 細胞のシグナル伝達, メディカルインターナショナル, 東京, 2016)
 
8) 市原栄基 : "分子標的治療薬概論", 304-7 (日本臨床腫瘍学会監修 : 新臨床腫瘍学 改訂5版. 南江堂, 東京, 2018)
 
9) 高野利実, 鶴谷純司, 福原傑 : "小分子化合物", 307-10 (日本臨床腫瘍学会監修 : 新臨床腫瘍学 改訂5版. 南江堂, 東京, 2018)
 
10) 多林孝之, 原浩樹, 原文堅, 梅村茂樹 : "抗体薬", 336-52 (日本臨床腫瘍学会監修 : 新臨床腫瘍学 改訂5版, 南江堂, 東京, 2018)
 
11) 各務博 : "免疫療法概論", 71-7 (日本がん治療認定医機構 教育委員会監修 : がん治療認定医教育セミナーテキスト 第13版, 日本がん治療認定医機構, 東京, 2019)
 
12) 成田有季哉 : "免疫チェックポイント阻害薬", 336-52 (日本臨床腫瘍学会監修 : 新臨床腫瘍学 改訂5版, 南江堂, 東京, 2018)
 
13) Ribas A : Tumor Immunotherapy Directed at PD-1. N Engl J Med 366 : 2517-9, 2012
PubMed
14) Chen SD, Mellman I : Oncology Meets Immunology : The Cancer-Immunity Cycle. Immunity 39 : 1-10, 2013
 

II章 遺伝子異常

P.28 掲載の参考文献
1) Wang J, Cazzato E, Ladewig E, et al : Clonal evolution of glioblastoma under therapy. Nature Genetics 48 : 768-76, 2016
 
2) Suzuki H, Aoki K, Chiba K, et al : Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics 47 : 458-68, 2015
PubMed
3) Toyota M, Ahuja N, Ohe-Toyota, M et al : CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96 : 8681-6, 1999
PubMed
4) Noushmehr H, Weisenberger DJ, Diefes K, et al : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell 17 : 510-22, 2010
PubMed
5) Verhaak RG, Hoadley KA, Purdom E, et al : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 : 98-110, 2010
PubMed
6) Piao Y, Liang J, Holmes L, et al : Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 19 : 4392-403, 2013
 
7) Segerman A, Niklasson M, Haglund C, et al : Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition. Cell Rep 17 : 2994-3009, 2016
PubMed
8) Parsons DW, Jones S, Zhang X, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-12, 2008
 
9) Balss J, Meyer J, Mueller W, et al : Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 116 : 597-602, 2008
PubMed
10) Ichimura K, Pearson DM, Kocialkowski S, et al : IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11 : 341-7, 2009
PubMed
11) Yan H, Parsons DW, Jin G et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-73, 2009
PubMed
12) Arita H, Narita Y, Yoshida A, et al : IDH1/2 mutation detection in gliomas. Brain Tumor Pathol 32 : 79-89, 2015
PubMed
13) Dang L, White DW, Gross S, et al : Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 : 739-44, 2009
PubMed
14) Xu W, Yang H, Liu Y, et al : Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19 : 17-30, 2011
 
15) Sanson M, Marie Y, Paris S, et al : Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27 : 4150-4, 2009
PubMed
16) Reifenberger J, Reifenberger G, Liu L, et al : Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145 : 1175-90, 1994
PubMed
17) Griffin CA, Burger P, Morsberger L, et al : Identification of de (r 1 ; 19) (q10 ; p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65 : 988-94, 2006
 
18) Cairncross JG, Ueki K, Zlatescu MC, et al : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 : 1473-9, 1998
PubMed
19) Ueki K, Nishikawa R, Nakazato Y, et al : Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8 : 196-201, 2002
PubMed
20) Vogazianou AP, Chan R, Backlund LM, et al : Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol 12 : 664-78, 2010
PubMed
21) Bettegowda C, Agrawal N, Jiao Y, et al : Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333 : 1453-5, 2011
PubMed
22) Arita H, Narita Y, Fukushima S, et al : Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126 : 267-76, 2013
PubMed
23) Killela PJ, Reitman ZJ, Jiao Y, et al : TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110 : 6021-6, 2013
 
24) Arita H, Narita Y, Takami H, et al : TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol 126 : 939-41, 2013
PubMed
25) Liu XY, Gerges N, Korshunov A, et al : Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124 : 615-25, 2012
PubMed
26) Louis DN, Ohgaki H, Wiestler OD, et al : World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon, 2016
 
27) Brennan CW, Verhaak RG, McKenna A, et al : The Somatic Genomic Landscape of Glioblastoma. Cell 155 : 462-77, 2013
PubMed
28) Brat DJ, Aldape K, Colman H, et al : cIMPACT-NOW update 3 : recommended diagnostic criteria for"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Europathol 136 : 805-10, 2018
PubMed
29) Hegi ME, Diserens AC, Gorlia T, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005
PubMed
30) Korber V, Yang J, Barah P, et al : Evolutionary Trajectories of IDH (WT) Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell 35 : 692-704 e612, 2019
 
P.38 掲載の参考文献
1) Taylor MD, Northcott PA, Korshunov A, et al : Molecular Subgroups of Medulloblastoma : The Current Consensus. Acta Neuropathol 123 : 465-72, 2012
PubMed
2) Juraschka K, Taylor MD : Medulloblastoma in the age of molecular subgroups : a review. J Neurosurg Pediatr 24 : 353-63, 2019
PubMed
3) Hovestadt V, Ayrault O, Swartling FJ, et al : Medulloblastomics revisited : biological and clinical insights from thousands of patients. Nat Rev Cancer 20 : 42-56, 2020
PubMed
4) Northcott PA, Buchhalter I, Morrissy AS, et al : The whole-genome landscape of medulloblastoma subtypes. Nature 547 : 311-7, 2017
PubMed
5) Korshunov A, Sahm F, Zheludkova O, et al : DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. Neuro Oncol 21 : 214-21, 2019
PubMed
6) Kool M, Jones DT, Jager N, et al : Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25 : 393-405, 2014
PubMed
7) Zhukova N, Ramaswamy V, Remke M, et al : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 : 2927-35, 2013
PubMed
8) Remke M, Ramaswamy V, Peacock J, et al : TERT Promoter Mutations Are Highly Recurrent in SHH Subgroup Medulloblastoma. Acta Neuropathol 126 : 917-29, 2013
PubMed
9) Ramaswamy V, Remke M, Bouffet E, et al : Risk Stratification of Childhood Medulloblastoma in the Molecular Era : The Current Consensus. Acta Neuropathol 131 : 821-31, 2016
PubMed
10) Goschzik T, Schwalbe EC, Hicks D, et al : Prognostic Effect of Whole Chromosomal Aberration Signatures in Standard-Risk, non-WNT/non-SHH Medulloblastoma : A Retrospective, Molecular Analysis of the HIT-SIOP PNET 4 Trial. Lancet Oncol 19 : 1602-16, 2018
 
11) Kilday JP, Mitra B, Domerg C, et al : Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification : a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 18 : 2001-11, 2012
 
12) Pajtler KW, Witt H, Sill M, et al : Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27 : 728-43, 2015
PubMed
13) Pajtler KW, Mack SC, Ramaswamy V, et al : The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133 : 5-12, 2017
PubMed
14) Lester A, McDonald KL : Intracranial ependymomas : molecular insights and translation to treatment. Brain Pathol 30 : 3-12, 2020
PubMed
15) Parker M, Mohankumar KM, Punchihewa C, et al : C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506 : 451-5, 2014
 
16) Fukuoka K, Kanemura Y, Shofuda T, et al : Significance of molecular classification of ependymomas : C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun 6 : 134, 2018
PubMed
17) Mack SC, Witt H, Piro RM, et al : Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 : 445-50, 2014
PubMed
18) Pajtler KW, Wen J, Sill M, et al : Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136 : 211-26, 2018
 
19) Cavalli FMG, Hubner JM, Sharma T, et al : Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 136 : 227-37, 2018
PubMed
20) Jones C, Baker SJ : Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14 : 10, 2014
PubMed
21) Jones C, Karajannis MA, Jones DTW, et al : Pediatric high-grade glioma : biologically and clinically in need of new thinking. Neuro Oncol 19 : 153-61, 2017
 
22) Roux A, Pallud J, Saffroy R, et al : High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts. Neuro Oncol, 2020 (in press)
 
23) Korshunov A, Ryzhova M, Hovestadt V, et al : Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129 : 669-78, 2015
PubMed
24) Ryall S, Tabori U, Hawkins C : Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8 : 30, 2020
PubMed
25) Ryall S, Zapotocky M, Fukuoka K, et al : Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 37 : 569-83, 2020
PubMed
26) 金村米博 : "家族性腫瘍 (遺伝性腫瘍症候群)", 197-209 (田村晃, 松谷雅生, 清水輝夫, ほか編 : 第4版 EBMに基づく脳神経疾患の基本治療指針. メジカルビュー社, 東京, 2016)
 
27) Malbari F, Lindsay H : Genetics of Common Pediatric Brain Tumors. Pediatr Neurol 104 : 3-12, 2020
PubMed
28) Waszak SM, Northcott PA, Buchhalter I, et al : Spectrum and Prevalence of Genetic Predisposition in Medulloblastoma : A Retrospective Genetic Study and Prospective Validation in a Clinical Trial Cohort. Lancet Oncol 19 : 785-98, 2018
 
29) Waszak SM, Robinson GW, Gudenas BL, et al : Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature 580 : 396-401, 2020
PubMed

III章 画像診断

P.46 掲載の参考文献
1) 荒木力監訳 : MRIの基本パワーテキスト 基礎理論から最新撮像法まで 第4版, メディカル・サイエンス・インターナショナル, 東京, 2019
 
2) Jain R. Johnson DR, Patel SH, et al : 'Real world' use of a highly reliable imaging sign : 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas. Neuro Oncol, 2020 doi : 10.1093/neuonc/noaa041.
 
P.53 掲載の参考文献
1) Singhal T, Narayanan TK, Jain V, et al : 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10 : 1-18, 2008
PubMed
2) 河井信行, 香川昌弘, 畠山哲宗, 他 : 脳腫瘍におけるメチオニンPET. No Shinkei Geka 36 : 847-59, 2008
 
3) Kato T, Shinoda J, Nakayama N, et al : Metabolic assessment of glioms using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29 : 1176-82, 2008
 
4) Derlon JM, Chapon F, Noel MH, et al : Non invasive grading of oligodendrogliomas : correlations between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27 : 778-87, 2000
PubMed
5) Kato T, Shinoda J, Oka N, et al : Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 29 : 1867-71, 2008
PubMed
6) Watanabe A, Muragaki Y, Maruyama T, et al : Usefulness of 11C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions. J Neurooncol 126 : 577-83, 2016
PubMed
7) Aki T, Nakayama N, Yonezawa S, et al : Evaluation of brain tumors using dynamic 11C-methionine-PET. J Neurooncol 109 : 115-22, 2012
 
8) Nomura Y, Asano Y, Shinoda J, et al : Characteristics of time-activity curves obtained from dynamic 11C-methionine PET in common primary brain tumors. J Neurooncol 138 : 649-58, 2018
 
9) Kracht LW, Miletic H, Busch S, et al : Delineation of brain tumor extent with [11C] L-methionine positron emission tomography : local comparison with stereotactic histopathology. Clin Cancer Res 10 : 7163-70, 2004
PubMed
10) Miwa K, Shinoda J, Yano H, et al : Discrepancy between lesion distributions on methionine PET and MR image in patients with glioblastoma multiforme : insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 75 : 1457-62, 2003
 
11) Inoue A, Ohnishi T, Kohno S, et al : Met-PET uptake index for total tumor resection : identification of 11C-methionine uptake index as a goal for total tumor resection including infiltrating tumor cells in glioblastoma. Neurosurg Rev 2020 Feb 15. [Epub ahead of print]
 
12) Pala A, Reske SN, Eberhardt N, et al : Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and 11C-methionine positron emission tomography in resection of glioblastoma : a prospective study. Neurosurg Rev 42 : 471-9, 2019
PubMed
13) Matsuo M, Miwa K, Tanaka O, et al : Impact of [11C] methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys 82 : 83-9, 2012
PubMed
14) Levivier M, Massager N, Wikler D, et al : Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors : clinical experience and proposed classification. J Nucl Med 45 : 1146-54, 2004
PubMed
15) Miwa K, Matsuo M, Ogawa S, et al : Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme. Biomed Res Int 2014 : 407026, 2014
PubMed
16) Miwa K, Matsuo M, Ogawa S, et al : Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat Oncol 9 : 181, 2014
PubMed
17) Nariai T, Tanaka T, Wakimoto H, et al : Usefulness of L- [methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103 : 498-507, 2005
 
18) Miwa K, Matsuo M, Shinoda J, et al : Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET : report of three cases. J Neurooncol 87 : 333-9, 2008
 
19) Kawasaki T, Miwa K, Shinoda J, et al : Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy. World Neurosurg 125 : 93-100, 2019
PubMed
20) Galldiks N, Kracht LW, Burghaus L, et al : Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33 : 516-24, 2006
PubMed
21) Tang BN, Sadeghi N, Branle F, et al : Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 71 : 161-8, 2005
PubMed
22) Tsuyuguchi N, Takami T, Sunada I, et al : Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma. Ann Nucl Med 18 : 291-6, 2004
PubMed
23) Terakawa Y, Tsuyuguchi N, Iwai Y, et al : Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49 : 694-9, 2008
PubMed
24) Takenaka S, Asano Y, Shinoda J, et al : Comparison of (11) C-methionine, (11) C-choline, and (18) F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo) 54 : 280-9, 2014
PubMed
25) Takei H, Shinoda J, Ikuta S, et al : Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. J Neurosurg (in press)
 

IV章 病理診断 ( 分子診断 )

P.62 掲載の参考文献
1) Committee of Brain Tumor Registry of Japan : Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 (Suppl.) : 9-102, 2017
 
2) Louis, DN, Ohgaki H, Wiestler OD, et al : WHO classification of tumours of the central nervous system, Revised 4th ed. International Agency for Research on Cancer (IARC) Press, Lyon, 2016
 
3) 日本脳神経外科学会, 日本病理学会編 : 脳腫瘍取扱い規約, 第4版, 金原出版, 東京, 2018
 
4) 日本脳腫瘍病理学会編 : 脳腫瘍病理カラーアトラス 第4版, 医学書院, 東京, 2017
 
5) 小森 隆司, 廣瀬 隆則編 : 腫瘍病理鑑別診断アトラス 脳腫瘍, 文光堂, 東京, 2017
 
6) Louis, DN, Perry A, Burger P, et al : International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24 : 429-35, 2014
PubMed
7) Komori T : The 2016 WHO Classification of Tumours of the Central Nervous System : The Major Points of Revision. Neurol Med Chir (Tokyo) 57 : 301-11, 2017
PubMed
8) Brat, DJ, Verhaak RG, Aldape KD, et al : Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372 : 2481-98, 2015
PubMed
9) Komori T : Updated 2016 WHO classification of tumors of the CNS : turning the corner where molecule meets pathology. Brain Tumor Pathol 34 : 139-140, 2017
PubMed
10) Louis DN, Aldape K, Brat DJ, et al : Announcing cIMPACT-NOW : the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133 : 1-3, 2017
 
11) Louis DN, Wesseling P, Paulus W, et al : cIMPACT-NOW update 2 : diagnostic criteria for diffuse midline glioma, H3K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135 : 481-84, 2018
 
12) Brat DJ, Aldape K, Colman H, et al : cIMPACT-NOW Update 3 : recommended diagnostic criteria for "diffuse astrocytic glioma, IDHwildtype, with molecular features of glioblastoma, WHO Grade IV". Acta Neuropathol 136 : 805-10, 2018
PubMed
13) Louis DN, Wesseling P, Aldape K, et al : cIMPACT-NOW update 6 : new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol, 2020 doi 10.1111/bpa.12832
 
14) Brat DJ, Aldape K, Colman H, et al : cIMPACT-NOW update 5 : recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol, 2020 doi 10.1007/s00401-020-02127-9
 
15) Komori T : The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community. Neuro Oncol 21 : 1485-6, 2019
PubMed
16) Komori T : Updating the grading criteria for adult diffuse gliomas : beyond the WHO2016CNS classification. Brain Tumor Pathol 37 : 1-4, 2019
 
17) 小森隆司 : 疾患診断標準化 : グリオーマの場合. 病理と臨床 38 : 793, 2020
 
P.72 掲載の参考文献
1) Ellison DW, Eberhart CG, Pietsch T, et al : Medulloblastoma, 184-8 (Ohgaki H, Wiestler OD, Cavenee WK, eds : World Health Organization Classification of Tumours of the Central Nervous System. Revised, 4th ed. IARC Press, Lyon, 2016)
 
2) Goschzik T, Zur Muhlen A, Kristiansen G, et al : Molecular stratification of medulloblastoma : comparison of histological and genetic methods to detect Wnt activated tumours. Neuropathol Appl Neurobiol 41 : 135-44, 2015
PubMed
3) Zhukova N, Ramaswamy V, Remke M, et al : Subgroup-specific prognostic implications of TP53 Mutation in medulloblastoma. J Clin Oncol 31 : 2927-35, 2013
PubMed
4) Takami H, Yoshida A, Fukushima S, et al : Revisiting TP53 mutations and immunohistochemistry-A comparative study in 157 diffuse gliomas. Brain Pathol 25 : 256-65, 2015
PubMed
5) Korshunov A, Remke M, Gessi M, et al : Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol 120 : 253-60, 2010
PubMed
6) Korshunov A, Sturm D, Ryzhova M, et al : Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol 128 : 279-89, 2014
PubMed
7) Kleinman CL, Gerges N, Papillon-Cavanagh S, et al : Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet 46 : 39-44, 2014
PubMed
8) Spence T, Sin-Chan P, Picard D, et al : CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 128 : 291-303, 2014
 
9) Korshunov A, Ryzhova M, Jones DTW, et al : LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124 : 875-81, 2012
PubMed
10) Sin-Chan P, Mumal I, Suwal T, et al : A C19MC-LIN28A-MYCN oncogenic circuit driven by hijacked super-enhancers is a distinct therapeutic vulnerability in ETMRs : a lethal brain tumor. Cancer Cell 35 : 51-67, 2019
 
11) Lambo S, Grobner SN, Rausch T, et al : The molecular landscape of ETMR at diagnosis and relapse. Nature 576 : 274-80, 2019
PubMed
12) Deisch J, Raisanen J, Rakheja D : Immunohistochemical expression of embryonic stem cell markers in malignant rhabdoid tumors. Pediatr Dev Pathol 14 : 353-9, 2011
PubMed
13) Biegel JA : Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 20 : E11, 2006
PubMed
14) Geller JI, Roth JJ, Biegel JA : Biology and treatment of rhabdoid tumor. Crit Rev Oncog 20 : 199-216, 2015
PubMed
15) Johann PD, Erkek S, Zapatka M, et al : Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29 : 1-15, 2016
 
16) Torchia J, Golbourn B, Feng S, et al : Integrated (epi) -genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer cell 30 : 891-908, 2016
PubMed

V章 手術

P.83 掲載の参考文献
1) Sanai N, Polley MY, McDermott MW, et al : An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115 : 3-8, 2011
PubMed
2) Lang FF, Sawaya R, Suki D, et al : Glioblastoma resection. J Neurosurg 116 : 1166-7 ; author reply 1167-8, 2012
 
3) Faust K, Schmiedek P, Vajkoczy P : Approaches to temporal lobe lesions : a proposal for classification. Acta Neurochir (Wien) 156 : 409-13, 2014
PubMed
4) Schramm J, Aliashkevich AF : Temporal mediobasal tumors : a proposal for classification according to surgical anatomy. Acta Neurochir (Wien) 150 : 857-64 ; discussion 864, 2008
PubMed
5) Shibahara I, Hanihara M, Miyasaka K, et al : Temporal Glioblastoma Mimicking Basal Ganglia Invasion : Distinguishing Removable and Unremovable Tumors. World Neurosurg 130 : e213-21, 2019
PubMed
6) Saito R, Kumabe T, Inoue T, et al : Magnetic resonance imaging for preoperative identification of the lenticulostriate arteries in insular glioma surgery. Technical note. J Neurosurg 111 : 278-81, 2009
PubMed
7) Fujii K, Lenkey C, Rhoton Jr AL : Microsurgical anatomy of the choroidal arteries : lateral and third ventricles. J Neurosurg 52 : 165-88, 1980
 
8) Morshed RA, Young JS, Han SJ, et al : The transcortical equatorial approach for gliomas of the mesial temporal lobe : techniques and functional outcomes. J Neurosurg : 1-9, 2018
 
P.94 掲載の参考文献
1) Lacroix M, Abi-said D, Fourney DR, et al : A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 95 : 190-8, 2001
PubMed
2) Sanai N, Polley MY, McDermott MW, et al : An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115 : 3-8, 2011
PubMed
3) Fukui A, Muragaki Y, Saito T, et al : Volumetric analysis using low-field intraoperative magnetic resonance imaging for 168 newly diagnosed supratentorial glioblastomas : Effects of extent of resection and residual tumor volume on survival and recurrence. World Neurosurg 98 : 73-80, 2017
PubMed
4) 村垣善浩 : 各論 グリオーマ (2). New How do you teach master Neurosurgical テクニック? 脳腫瘍編. 脳外速報 19 : 764-9, 2009
 
5) Ribas GC, Yasuda A, Ribas EC, et al : Surgical anatomy of meicrosurgical sulcal key points. Neurosurgery 59 (ONS Suppl 4) : 177-211, 2006
 
6) Koriyama S, Nitta M, Shioyama T, et al : Intraoperative flow cytometry enables the differentiation of primary central nervous system lymphoma from glioblastoma. World Neurosurg 112 : 261-8, 2018
 
7) Shioyama T, Muragaki Y, Maruyama T, et al : Intraoperative flow cytometry analysis of glioma tissue for rapid determination of tumor presence and its histopathological grade : clinical article. J Neurosurg 118 : 1232-8, 2013
PubMed
8) Saito T, Muragaki Y, Shioyama T, et al : Malignancy index using intraoperative flow cytometry is a valuable prognostic factor for glioblastoma treated with radiotherapy and concomitant temozolomide. Neurosurgery 84 : 662-72, 2019
PubMed
9) Koriyama S, Nitta M, Kobayashi T, et al : A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis. Brain Tumor Pathol 35 : 159-67, 2018
PubMed
10) Muragaki Y, Akimoto J, Maruyama T, et al : Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg 119 : 845-52, 2013
PubMed
11) Konishi Y, Muragaki Y, Iseki H, et al : Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management : restrospective analysis of 43 cases. Neurol Med Chir (Tokyo) 52 : 577-86, 2012
 
12) Dayani F, Young JS, Bonte A, et al : Safety and outcomes of resection of butterfly glioblastoma. Neurosurg Focus 44 : E4, 2018
PubMed
P.103 掲載の参考文献
1) Stupp R, Hegi ME, Mason WP, et al : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 : 459-66, 2009
 
2) Neftel C, Laffy J, Filbin MG, et al : An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178 : 835-49 e21, 2019
 
3) Chinot OL, Wick W, Mason W, et al : Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370 : 709-22, 2014
PubMed
4) Reardon DA, Brandes AA, Omuro A, et al : Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma : The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020 May 21 ; e201024
 
5) Marko NF, Weil RJ, Schroeder JL, et al : Extent of resection of glioblastoma revisited : personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol 32 : 774-82, 2014
PubMed
6) Molinaro AM, Hervey-Jumper S, Morshed RA, et al : Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol 6 : 495-503, 2020
PubMed
7) Lee JH, Lee JE, Kahng JY, et al : Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560 : 243-7, 2018
PubMed
8) Snuderl M, Fazlollahi L, Le LP, et al : Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20 : 810-7, 2011
PubMed
9) Hegi ME, Diserens AC, Gorlia T, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005
PubMed
10) Johnson BE, Mazor T, Hong C, et al : Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 : 189-93, 2014
PubMed
11) Touat M, Li YY, Boynton AN, et al : Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580 : 517-23, 2020
PubMed
12) Parsons DW, Jones S, Zhang X, et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-12, 2008
 
13) Venteicher AS, Tirosh I, Hebert C, et al : Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355 : eaai8478, 2017
PubMed
14) Brat DJ, Aldape K, Colman H, et al : cIMPACT-NOW update 5 : recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139 : 603-8, 2020
PubMed
15) Wefel JS, Noll KR, Rao G, et al : Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 18 : 1656-63, 2016
PubMed
16) Beiko J, Suki D, Hess KR, et al : IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16 : 81-91, 2014
PubMed
17) Andronesi OC, Loebel F, Bogner W, et al : Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clini Cancer Res 22 : 1632-41, 2016
 
18) Jafari-Khouzani K, Loebel F, Bogner W, et al : Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol 18 : 1569-78, 2016
PubMed
19) Shankar GM, Kirtane AR, Miller JJ, et al : Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A 115 : E8388-94, 2018
PubMed
20) Suzuki H, Aoki K, Chiba K, et al : Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47 : 458-68, 2015
PubMed
21) Arita H, Yamasaki K, Matsushita Y, et al : A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4 : 79, 2016
PubMed
22) Aoki K, Nakamura H, Suzuki H, et al : Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20 : 66-77, 2018
PubMed
23) Appay R, Dehais C, Maurage CA, et al : CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21 : 1519-28, 2019
 
24) Tateishi K, Nakamura T, Juratli TA, et al : PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res 25 : 4375-87, 2019
PubMed
25) Patel SH, Poisson LM, Brat DJ, et al : T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas : A TCGA/TCIA Project. Clin Cancer Res 23 : 6078-85, 2017
PubMed
26) Kawaguchi T, Sonoda Y, Shibahara I, et al : Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neuro-oncol 129 : 505-14, 2016
 
27) Shirahata M, Ono T, Stichel D, et al : Novel, improved grading system (s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136 : 153-66, 2018
PubMed
28) Rohle D, Popovici-Muller J, Palaskas N, et al : An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 : 626-30, 2013
PubMed
29) Tateishi K, Wakimoto H, Iafrate AJ, et al : Extreme Vulnerability of IDH1 Mutant Cancers to NAD+Depletion. Cancer Cell 28 : 773-84, 2015
PubMed
30) Schumacher T, Bunse L, Pusch S, et al : A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512 : 324-7, 2014
PubMed
31) Sulkowski PL, Corso CD, Robinson ND, et al : 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med 9 : eaal2463, 2017
PubMed
32) Killela PJ, Reitman ZJ, Jiao Y, et al : TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110 : 6021-6, 2013
 
33) Brat DJ, Aldape K, Colman H, et al : cIMPACT-NOW update 3 : recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 136 : 805-10, 2018
PubMed
34) Juratli TA, Stasik S, Zolal A, et al : TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas : A Pilot Prospective Study. Clin Cancer Res 24 : 5282-91, 2018
PubMed
35) Tateishi K, Tateishi U, Nakanowatari S, et al : (62) Cu-diacetyl-bis (N (4) -methylthiosemicarbazone) PET in human gliomas : comparative study with [(18) F] fluorodeoxyglucose and L-methyl- [(11) C] methionine PET. AJNR Am J Neuroradiol 35 : 278-84, 2014
PubMed
36) Tateishi K, Tateishi U, Sato M, et al : Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1alpha expression in patients with glioma. AJNR Am J Neuroradiol 34 : 92-9, 2013
PubMed
37) Takahashi M, Miki S, Fujimoto K, et al : Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci 110 : 2247-57, 2019
PubMed
38) Wakimoto H, Tanaka S, Curry WT, et al : Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20 : 2898-909, 2014
PubMed
39) Tateishi K, Iafrate AJ, Ho Q, et al : Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22 : 4452-65, 2016
PubMed
40) Tateishi K, Higuchi F, Miller JJ, et al : The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+Depletion-Mediated Cytotoxicity. Cancer Res 77 : 4102-15, 2017
PubMed
P.112 掲載の参考文献
1) Aoki T, Nishikawa R, Sugiyama K, et al : A multicenter phase I/II study of the BCNU implant (Gliadel (R) Wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 54 : 290-301, 2014
 
2) Fung LK, Ewend MG, Sills A, et al : Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58 : 672-84, 1998
PubMed
3) Ohue S, Kohno S, Inoue A, et al : Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence. J Neurooncol 126 : 119-26, 2016
PubMed
4) Brem H, Mahaley MS Jr, Vick NA, et al : Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74 : 441-6, 1991
PubMed
5) Brem H, Piantadosi S, Burger PC, et al : Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345 : 1008-12, 1995
PubMed
6) Westphal M, Hilt DC, Bortey E, et al : A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 : 79-88, 2003
 
7) Stupp R, Mason WP, van den Bent MJ, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-96, 2005
PubMed
8) Stummer W, van den Bent MJ, Westphal M : Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies : new arguments in an old discussion. Acta Neurochir (Wien) 153 : 1211-8, 2011
 
9) Sonoda Y, Shibahara I, Matsuda KI, et al : Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers : a multi-center retrospective study. J Neurooncol 134 : 83-8, 2017
PubMed
10) Sabel M, Giese A : Safety profile of carmustine wafers in malignant glioma : a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 24 : 3239-57, 2008
 
11) Ashby LS, Smith KA, Stea B : Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma : a systematic literature review. World J Surg Oncol 14 : 225, 2016
PubMed
12) Gallego JM, Barcia JA, Barcia-Marino C : Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 149 : 261-5, 2007
PubMed
13) Sato K, Dan M, Yamamoto D, et al : Chronic Phase Intracranial Hemorrhage Caused by Ruptured Pseudoaneurysm Induced by Carmustine Wafer Implantation for Insulo-opercular Anaplastic Astrocytoma : A Case Report. Neurol Med Chir (Tokyo) 55 : 848-51, 2015
PubMed
14) Saito K, Yamasaki K, Yokogami K, et al : Eosinophilic meningitis triggered by implanted Gliadel wafers : case report. J Neurosurg 126 : 1783-7, 2017
PubMed
15) Chowdhary SA, Ryken T, Newton HB : Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas : a meta-analysis. J Neurooncol 122 : 367-82, 2015
PubMed
16) Gutenberg A, Lumenta CB, Braunsdorf WE, et al : The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 113 : 163-74, 2013
PubMed
P.124 掲載の参考文献
1) Sanai N, Polley MY, McDermott MW, et al : An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115 : 3-8, 2011
PubMed
2) Patel SH, Poisson LM, Brat DJ, et al : T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas : a TCGA/TCIA Project. Clin Cancer Res 23 : 6078-85, 2017
PubMed
3) Kawaguchi T, Sonoda Y, Shibahara I, et al : Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 129 : 505-14, 2016
PubMed
P.134 掲載の参考文献
1) Smith JS, Chang EF, Lamborn KR, et al : Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26 : 1338-45, 2008
 
2) Pallud J, Capelle L, Taillandier L, et al : Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neurooncol 11 : 176-82, 2009
 
3) Fukushima S, Narita Y, Miyakita Y, et al : A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy. Neuropathology 33 : 576-81, 2013
PubMed
4) 成田善孝, 嘉山孝正 : グリオーマの覚醒下手術の基本. 脳外速報 21 : 482-90, 2011
Medical*Online
5) 成田善孝 : "神経上皮系腫瘍 : 神経膠腫grade II・III", 98-116 (EBMに基づく脳神経疾患の基本治療指針, 第4版, メジカルビュー社, 東京, 2016)
 
6) Akashi T, Takahashi S, Mugikura S, et al : Ischemic White Matter Lesions Associated With Medullary Arteries : Classification of MRI Findings Based on the Anatomic Arterial Distributions. AJR Am J Roentgenol 209 : W160-W168, 2017
PubMed
P.145 掲載の参考文献
1) CUSA(R) Excel Technical Brief, Integra (R)
 
2) 園田順彦 : グリオーマ摘出時の虚血合併症の予防法は?, 187-8 (吉村紳一監修, 吉本幸司編 : 疾患・術式別 脳神経外科手術合併症の回避・対処法 Q&A 156. 脳外速報2019年増刊, 2019)
 
3) 山本淳考, 北川雄大, 宮岡亮ほか : グリオーマ治療と光感受性物質～5-アミノレブリン酸を中心に～. Neuro-Oncologyの進歩 25 : 13-21, 2018
 
4) 中田光俊 : 脳腫瘍摘出術におけるフェンスポスト法. 脳外速報 26 : 914-21, 2016
Medical*Online
5) Motomura K, et al : Surgical benefits of combined awake craniotomy and intraoperative magnetic resonance imaging for gliomas associated with eloquent areas. J Neurosurg 127 : 790-7, 2017
 
P.156 掲載の参考文献
1) Sanai N, Polley MY, Berger MS : Insular Glioma Resection : Assessment of Patient Morbidity, Survival, and Tumor Progression. J Neurosurg 112 : 1-9, 2010
PubMed
2) 丸山隆志, 村垣善浩 : Transcortical approach, 島回腫瘍への経皮質アプローチ. 42-5 (松谷雅生, 堀智勝, 浅野孝雄監修, 塩川芳昭, 斉藤延人, 川原信隆, 他編 : 新 脳神経外科手術のための解剖学. メジカルビュー社, 東京, 2019)
 
3) Kumabe T, Higano S, Takahashi S, et al : Ischemic Complications Associated With Resection of Opercular Glioma. J Neurosurg 106 : 263-9, 2007
PubMed
P.163 掲載の参考文献
1) De Witt Hamer PC, Robles SG, Zwinderman AH, et al : Impact of intraoperative stimulation brain mapping on glioma surgery outcome : a meta-analysis. J Clin Oncol 30 : 2559-65, 2012
PubMed
2) 中田光俊 : 覚醒下手術ことはじめ. 中外医学社, 東京, 2019
 
3) 中田光俊, 木下雅史, 中嶋 理帆ほか : 右前頭葉の機能局在と覚醒下手術. 脳外誌 26 : 657-67, 2017
 
4) Kayama T : The guidelines for awake craniotomy guidelines committee of the Japan awake surgery conference. Neurol Med Chir (Tokyo) 52 : 119-41, 2012
PubMed
5) Bartolomeo P, Thiebaut de Schotten M, Duffau H : Mapping of visuospatial functions during brain surgery : a new tool to prevent unilateral spatial neglect. Neurosurgery 61 : E1340, 2007
PubMed
6) Kinoshita M, Nakajima R, Shinohara H, et al : Chronic spatial working memory deficit associated with the superior longitudinal fasciculus : a study using voxel-based lesion-symptom mapping and intraoperative direct stimulation in right prefrontal glioma surgery. J Neurosurg 125 : 1024-32, 2016
PubMed
7) Nakajima R, Kinoshita M, Okita H, et al : Neural Networks Mediating High-Level Mentalizing in Patients With Right Cerebral Hemispheric Gliomas. Front Behav Neurosci 12 : 33, 2018
PubMed
8) Saito T, Muragaki Y, Maruyama T, et al : Difficulty in identification of the frontal language area in patients with dominant frontal gliomas that involve the pars triangularis. J Neurosurg 125 : 803-11, 2016
PubMed
9) Duffau H : Is non-awake surgery for supratentorial adult low-grade glioma treatment still feasible? Neurosurg Rev 41 : 133-9, 2018
PubMed
10) 中田光俊, 中嶋理帆, 玉井翔ほか : 脳機能温存に留意したグリオーマ治療. 脳外誌 28 : 686-98, 2019
 
P.172 掲載の参考文献
1) Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 (Sup 1) : s9-102, 2017
 
2) 高倉公朋, 斎藤勇, 佐藤潔 (編) : 脳室とその近傍. 図説脳神経外科New Approach, メジカルビュー社, 東京, 1997
 
3) 荒川芳輝 : 脳腫瘍の手術のための術前・術中支援 大脳深部髄内腫瘍に対する開頭術, 内視鏡手術. No Shinkei Geka 45 : 549-62, 2017
 
P.182 掲載の参考文献
1) 日本脳腫瘍学会編, 日本脳神経外科学会監修 : 脳腫瘍診療ガイドライン 2019年版, 金原出版, 東京, 2019. pp.119. https://www.jsn-o.com/guideline3/CQ/016.html
 
2) Khe Hoang-Xuan, Eric Bessell, Jacoline Bromberg, et al : Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients : guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16 : e322-32, 2015
PubMed
3) National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/default_nojava.aspx#site
 
4) K Murray, L Kun, J Cox : Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg 65 : 600-7, 1986
 
5) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 Suppl : 9, 2017
 
6) Catherine H Han, Tracy T Batchelor : Diagnosis and management of primary central nervous system lymphoma. Cancer 123 : 4314-24, 2017
PubMed
7) Hideo Nakamura, Keishi Makino, Shigetoshi Yano, et al : Epidemiological study of primary intracranial tumors : a regional survey in Kumamoto prefecture in southern Japan : 20-year study. Int J Clin Oncol 16 : 314-21, 2011
PubMed
8) Patrick G Morris, Denise D Correa, Joachim Yahalom, et al : Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma : final results and long-term outcome. J Clin Oncol 31 : 3971-9, 2013
PubMed
9) Caroline Houillier, Luc Taillandier, Sylvain Dureau, et al : Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger : Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol 37 : 823-33, 2019
 
10) Michail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al : Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 31 : 833-43, 2017
PubMed
11) Ava Brozovich, Donald Ewing, Ethan Burns, et al : Primary CNS Lymphoma Arising from the 4 th Ventricle : A Case Report and Review of the Literature. Case Rep Oncol Med 10 : 2671794, 2019
 
12) Vijay Seevaratnam, Yingda Li, Sun Loong Keegan Lee, et al : Primary central nervous system lymphoma at the cerebellopontine angle mimicking a trigeminal schwannoma : A unique case report and literature review. J Clin Neurosci 52 : 115-9, 2018
PubMed
13) B Bataille, V Delwail, E Menet, et al : Primary intracerebral malignant lymphoma : report of 248 cases. J Neurosurg 92 : 261-6, 2000
 
14) Yuta Shibamoto, Minako Sumi, Shunsuke Onodera, et al : Primary CNS lymphoma treated with radiotherapy in Japan : a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004. Int J Clin Oncol 19 : 963-71, 2014
 
15) John Y Choi, Chrysanthi Kafkala, C Stephen Foster : Primary intraocular lymphoma : A review. Semin Ophthalmol 21 : 125-33, 2006
PubMed
16) Alexis A Morell, Ashish H Shah, Claudio Cavallo, et al : Diagnosis of primary central nervous system lymphoma : a systematic review of the utility of CSF screening and the role of early brain biopsy. Neurooncol Pract 6 : 415-23, 2019
PubMed
17) Sivri M, Erdogan H, Allahverdiyev I, et al : A rare cause of spinal mass : primary intramedullary spinal cord lymphoma. Spine J 15 : e43-4, 2015
PubMed
18) Lauren E Abrey, Tracy T Batchelor, Andres J M Ferreri, et al : Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 : 5034-43, 2005
PubMed
19) Kristoph Jahnke, Michael Hummel, Agnieszka Korfel, et al : Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24 : 4754-7, 2006
PubMed
20) Alexander C Guo, Thomas J Cummings, Rajesh C Dash, et al : Lymphomas and high-grade astrocytomas : comparison of water diffusibility and histologic characteristics. Radiology 224 : 177-83, 2002
PubMed
21) Todd A Hardy, Jeremy Chataway : Tumefactive demyelination : an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 84 : 1047-53, 2013
PubMed
22) Lucchinetti CF, Gavrilova RH, Metz I, et al : Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 : 1759-75, 2008
PubMed
23) Michael G Z Ghali : Tumefactive Acute Disseminated Encephalomyelitis. Neurol India 68 : 35-41, 2020
PubMed
24) Jennifer L McGuire, Vera Fridman, Christian Wuthrich, et al : Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS. J Neurovirol 17 : 500-3, 2011
 
25) Sanahuja J, Ordonez-Palau S, Begue R, et al : Primary Sjogren syndrome with tumefactive central nervous system involvement. AJNR 29 : 1878-9, 2008
PubMed
26) Bennett DLH, McCabe DJH, Stevens JM, et al : Tumefactive neuro-Behcet disease. Neurology 63 : 709, 2004
PubMed
27) Sonia Partap, Alexander M Spence : Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man. J Neurooncol 80 : 305-7, 2006
 
28) M Al-Yamany, A Lozano, S Nag, et al : Spontaneous remission of primary central nervous system lymphoma : report of 3 cases and discussion of pathophysiology. J Neurooncol 42 : 151-9, 1999
 
29) Alderson L, Fetell MR, Sisti M, et al : Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 60 : 102-5, 1996
PubMed
30) R Bakshi, J C Mazziotta, P S Mischel, et al : Lymphomatosis cerebri presenting as a rapidly progressive dementia : clinical, neuroimaging and pathologic findings. Dement Geriatr Cogn Disord 10 : 152-7, 1999
 
31) M Weller : Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 43 : 237-9, 1999
 
32) Manoj N, Arivazhagan A, Mahadevan A, et al : Central nervous system lymphoma : patterns of incidence in Indian population and effect of steroids on stereotactic biopsy yield. Neurol India 62 : 19-25, 2014
 
33) Yasuko Ohe, Takeshi Hayashi, Kazuhiko Mishima, et al : Central nervous system lymphoma initially diagnosed as tumefactive multiple sclerosis after brain biopsy. Intern Med 52 : 483-8, 2013
PubMed
34) James B Elder, Thomas C Chen : Surgical interventions for primary central nervous system lymphoma. Neurosurg Focus 21 : E13, 2006
PubMed
35) Rose Lai, Marc K Rosenblum, Lisa M DeAngelis : Primary CNS lymphoma : a whole-brain disease? Neurology 59 : 1557-62, 2002
PubMed
36) Shibamoto Y, Hayabuchi N, Hiratsuka J, et al : Is whole-brain irradi- ation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97 : 128-33, 2003
 
37) W Sonstein, K Tabaddor, J F Llena : Solitary primary CNS lymphoma : long term survival following total resection. Med Oncol 15 : 61-5, 1998
 
38) K G Davies, G C Cole, R D Weeks : Twenty-year survival following excision of primary CNS lymphoma without radiation therapy : case report. Br J Neurosurg 8 : 487-91, 1994
 
39) M Bellinzona, F Roser, H Ostertag, et al : Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions : a series of 33 cases. Eur J Surg Oncol 31 : 100-5, 2005
 
40) Michael Weller, Peter Martus, Patrick Roth, et al : Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14 : 1481-4, 2012
PubMed
41) Andres J M Ferreri, Jean-Yves Blay, Michele Reni, et al : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 : 266-72, 2003
 
42) Guro Jahr, Michele Da Broi, Harald Holte Jr, et al : The role of surgery in intracranial PCNSL. Neurosurg Rev 41 : 1037-44, 2018
PubMed
43) Ali I Rae, Amol Mehta, Michael Cloney, et al : Craniotomy and Survival for Primary Central Nervous System Lymphoma. Neurosurgery 84 : 935-44, 2019
PubMed
44) Michael Brendan Cloney, Adam M Sonabend, Jonathan Yun, et al : The safety of resection for primary central nervous system lymphoma : a single institution retrospective analysis. Neurooncol 132 : 189-97, 2017
PubMed
45) Jonathan Yun, Jingyan Yang, Michael Cloney, et al : Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma : A Nationwide Inpatient Sample Analysis. Front Neurol 8 : 478, 2017
PubMed
P.194 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 Suppl : 14-6, 2017
 
2) Kanamori M, Kumabe T, Watanabe M, et al : Indications for salvage surgery during treatment for intracranial germ cell tumors. J Neurooncol 138 : 601-7, 2018
PubMed
3) Kanamori M, Kumabe T, Tominaga T : Is histological diagnosis necessary to start treatment for germ cell tumours in the pineal region? J Clin Neurosci 15 : 978-87, 2008
PubMed
4) Sawamura Y, Kato T, Ikeda J, et al : Teratomas of the central nervous system : treatment considerations based on 34 cases. J Neurosurg 89 : 728-37, 1998
 
5) Mano Y, Kanamori M, Kumabe T, et al : Extremely Late Recurrence 21 Years after Total Removal of Immature Teratoma : A Case Report and Literature Review. Neurol Med Chir (Tokyo) 57 : 51-6, 2017
PubMed
6) Weiner HL, Lichtenbaum RA, Wisoff JH, et al : Delayed surgical resection of central nervous system germ cell tumors. Neurosurgery 50 : 727-34, 2002
PubMed
7) Takami H, Perry A, Graffeo CS, et al : Novel Diagnostic Methods and Posttreatment Clinical Phenotypes Among Intracranial Germ Cell Tumors [published online ahead of print, 2020 Apr 29]. Neurosurgery, 2020 ; nyaa108. doi : 10.1093/neuros/nyaa108
 
8) Chiba K, Aihara Y, Komori T, et al : Placental alkaline phosphatase in cerebrospinal fluid as a biomarker for optimizing surgical treatment strategies for pineal region germ cell tumors. Brain Tumor Pathol 37 : 60-8, 2020
PubMed
9) Kochi M, Itoyama Y, Shiraishi S, et al : Successful treatment of intracranial nongerminomatous malignant germ cell tumors by administering neoadjuvant chemotherapy and radiotherapy before excision of residual tumors. J Neurosurg 99 : 106-14, 2003
PubMed
10) Suzuki Y, Nakajima M, Ikeda H, et al : Three-dimensional computed tomography angiography of the galenic system for the occipital transtentorial approach. Neurol Med Chir (Tokyo) 45 : 387-94, 2005
PubMed
11) Rhoton AL : Cranial anatomy and surgical approaches, 142 (Lippincott, Williams & Wilkins. Philadelphia, 2007)
 
12) Saito R, Kumabe T, Kanamori M, et al : Medial posterior choroidal artery territory infarction associated with tumor removal in the pineal/tectum/thalamus region through the occipital transtentorial approach. Clin Neurol Neurosurg 115 : 1257-63, 2013
PubMed
13) Matsuo S, Baydin S, Gungor A, et al : Midline and off-midline infratentorial supracerebellar approaches to the pineal gland. J Neurosurg 126 : 1984-94, 2017
 
14) Suzuki J, Katakura R, Mori T : Interhemispheric approach through the lamina terminalis to tumors of the anterior part of the third ventricle. Surg Neurol 22 : 157-63, 1984
PubMed
15) 佐々木達也, 児玉南海雄, 小林亨, 他 : 第三脳室底の微小外科解剖と第三脳室経由到達法, 123-33 (松島俊夫編 : 顕微鏡下手術のための脳神経外科解剖 VI. サイメッドパブリケーションズ, 東京, 1994)
 
16) 大畑建治, 馬場元毅, 内田耕一 : 手術のための脳局所解剖学, 35 (馬場元毅, 大畑建治著, (中外医学社, 東京 35, 2008)
 
17) Gomes FB, Dujovny M, Umansky F, et al : Microanatomy of the anterior cerebral artery. Surg Neurol 26 : 129-41, 1986
PubMed
18) Carmel PW : Surgical syndromes of the hypothalamus. Clin Neurosurg 27 : 133-59, 1980
PubMed
P.201 掲載の参考文献
1) Thompson EM, Hielscher T, Bouffet E, et al : Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup : a retrospective integrated clinical and molecular analysis. Lancet Oncol 17 : 484-95, 2016
PubMed
2) Spennato P, Nicosia G, Quaglietta L, et al : Posterior fossa tumors in infants and neonates. Childs Nerv Syst 31 : 1751-72, 2015
PubMed
3) Ruggiero C, Cinalli G, Spennato P, et al : Endoscopic third ventriculostomy in the treatment of hydrocephalus in posterior fossa tumors in children. Childs Nerv Syst 20 : 828-33, 2004
 
P.210 掲載の参考文献
1) 中洲庸子, 三矢幸一, 林央周, 他 : 転移性脳腫瘍の「最小限摘出」と「安全域付き切除」-浸潤境界を基にした摘出術の使い分け-. 脳神経外科 44 : 221-6, 2016
 
2) 中洲庸子, 三矢幸一, 出口彰一, 他 : 転移性脳腫瘍に対する摘出術-局所再発と髄膜播種の分析から個別の治療戦略へ-. 脳神経外科 46 : 185-95, 2018
 
3) Black PM, Johnson MD : Surgical resection for patients with solid brain metastases : current status. J Neurooncol 69 : 119-24, 2004
PubMed
4) Narita Y, Shibui S : Strategy of surgery and radiation therapy for brain metastases. Int J Clin Oncol 14 : 275-80, 2009
PubMed
5) 高橋英明 : 転移性脳腫瘍に対する外科治療. 癌の臨 62 : 61-8, 2016
Medical*Online
6) 三矢幸一, 中洲庸子, 大野幸代, 他 : 術中綿片洗浄細胞診 (コットンダム細胞診) -転移性脳腫瘍摘出術における髄膜播種の評価と予防のために-. 脳神経外科 45 : 29-32, 2017
 
7) Nguyen TK, Sahgal A, Detsky J, et al : Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases. Neuro Oncol 22 : 84-93, 2020
PubMed
8) Kayama T, Sato S, Sakurada K, et al : Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504) : a phase III, noninferiority, randomized controlled trial. J Clin Oncol 36 : 3282-89, 2018
 
9) Baumert BG, Rutten I, Dehing-Oberije C, et al : A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 66 : 187-94, 2006
PubMed
10) Siam L, Bleckmann A, Chaung HN, et al : The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study. Oncotarget 6 : 29254-67, 2015
 
11) Suki D, Hatiboglu MA, Patel AJ, et al : Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery 64 : 664-74, 2009
PubMed
12) Mitsuya K, Nakasu Y, Hayashi N, et al : Retrospective analysis of salvage surgery for local progression of brain metastasis previously treated with stereotactic irradiation : diagnostic contribution, functional outcome, and prognostic factors. BMC Cancer 20 : 331, 2020
PubMed
13) Suki D, Abouassi H, Patel AJ, et al : Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 108 : 248-57, 2008
PubMed
14) Ahn JH, Lee SH, Kim S, et al : Risk for leptomeningeal seeding after resection for brain metastases : implication of tumor location with mode of resection. J Neurosurg 116 : 984-93, 2012
PubMed
15) Susko M, Yu Y, Ma L, et al : Preoperative Dural Contact and Recurrence Risk After Surgical Cavity Stereotactic Radiosurgery for Brain Metastases : New Evidence in Support of Consensus Guidelines. Adv Radiat Oncol 4 : 458-65, 2019
PubMed
16) Okuda T, Teramoto Y, Yugami H, et al : Surgical technique for a cystic-type metastatic brain tumor : transformation to a solid-type tumor using hydrofiber dressing. Surg Neurol 72 : 703-6, 2009
PubMed
17) Okuda T, Fujita M, Yoshioka H, et al : Novel surgical technique to solidify cyst-type metastatic brain tumors using autologous fibrin glue for complete resection. Surg Neurol Int 5 : 100, 2014
PubMed
18) Uzuka T, Takahashi H, Nakasu Y, et al : Surgical Site Infection after Malignant Brain Tumor Resection : A Multicenter Study for Induction of a Basic Care Bundle. Neurol Med Chir (Tokyo) 57 : 542-7, 2017
PubMed
19) Patchell RA, Tibbs PA, Regine WF, et al : Postoperative radiotherapy in the treatment of single metastases to the brain : a randomized trial. JAMA 280 : 1485-9, 1998
 
20) Mahajan A, Ahmed S, McAleer MF, et al : Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases : a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18 : 1040-8, 2017
PubMed
21) Brown PD, Ballman KV, Cerhan JH, et al : Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC・3) : a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18 : 1049-60, 2017
 
22) Mitsuya K, Nakasu Y, Narita Y, et al : "Comet tail sign" : A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors. J Neurooncol 127 : 589-95, 2016
PubMed

VI章 補助療法

P.218 掲載の参考文献
1) 大西洋, 唐澤久美子, 唐澤克之編 : がん放射線療法 2017 改訂第7版. 学研メディカル秀潤社, 東京, 2017
 
2) 日本放射線腫瘍学会編 : 放射線治療計画ガイドライン 2016年度版. 金原出版, 東京, 2016
 
3) Niyazi M, Brada M, Chalmers AJ, et al : ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol 118 : 35-42, 2016
PubMed
4) Minniti G, Capone L, Nardiello B, et al : Neurological outcome and memory performance in patients with 10 or more brain metastases treated with frameless linear accelerator (LINAC) -based stereotactic radiosurgery. J Neurooncol 148 : 47-55, 2020
PubMed
5) Hartgerink D, Swinnen A, Roberge D, et al : LINAC based stereotactic radiosurgery for multiple brain metastases : guidance for clinical implementation. Acta Oncol 58 : 1275-82, 2019
PubMed
6) Navarria P, Minniti G, Clerici E, et al : Re-irradiation for recurrent glioma : outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol 142 : 59-67, 2019
PubMed
P.227 掲載の参考文献
1) Barth RF, Vicente MG, Harling OK, et al : Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 7 : 146, 2012
PubMed
2) Farr LE, Sweet WH, Robertson JS, et al : Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med 71 : 279-293, 1954
PubMed
3) Hatanaka H, Nakagawa Y：Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28 : 1061-6, 1994
PubMed
4) Kawabata S, Miyatake S, Kuroiwa T, et al : Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res 50 : 51-60, 2009
PubMed
5) Yamamoto T, Nakai K, Kageji T, et al : Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 91 : 80-4, 2009
PubMed
6) Henriksson R, Capala J, Michanek A, et al : Boron neutron capture therapy (BNCT) for glioblastoma multiforme : a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 88 : 183-91, 2008
PubMed
7) Skold K, Gorlia T, Pellettieri L, et al : Boron neutron capture therapy for newly diagnosed glioblastoma multiforme : an assessment of clinical potential. Br J Radiol 83 : 596-603, 2010
PubMed
8) Pellettieri L, B HS, Rezaei A, et al : An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand 117 : 191-7, 2008
 
9) Miyatake SI, Kawabata S, Yokoyama K, et al : Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neuro-Oncol 91 : 199-206, 2009
 
10) Shiba H, Takeuchi K, Hiramatsu R, et al : Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas-A Pilot Study. Neurol Med Chir (Tokyo) 58 : 487-94, 2018
PubMed
11) Suzuki M, Kato I, Aihara T, et al : Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res 55 : 146-53, 2014
PubMed
12) Kiger WS 3rd, Palmer MR, Riley KJ, et al : Pharamacokinetic modeling for boronophenylalanine-fructose mediated neutron capture therapy : 10B concentration predictions and dosimetric consequences. J Neuro oncol 62 : 171-86, 2003
 
13) Mayer R, Sminia P：Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70 : 1350-60, 2008
PubMed
14) Kawabata S, Hiramatsu R, Kuroiwa T, et al : Boron neutron capture therapy for recurrent high-grade meningiomas. J neurosurg 119 : 837-44, 2013
PubMed
15) Takeuchi K, Kawabata S, Hiramatsu R, et al : Boron Neutron Capture Therapy for High-Grade Skull-Base Meningioma. J Neurol Surg B Skull Base 79 : S322-S7, 2018
PubMed
P.235 掲載の参考文献
1) Paganetti H, Niemierko A, Ancukiewicz M, et al : Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys 53 : 407-21, 2002
PubMed
2) Kortmann RD, Timmermann B, Taylor RE, et al : Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II : Treatment-related late toxicity. Strahlenther Onkol 179 : 585-97, 2003
PubMed
3) Armstrong GT, Liu Q, Yasui Y, et al : Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101 : 946-58, 2009
PubMed
4) Merchant TE, Kiehna EN, Li C, et al : Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. Int J Radiat Oncol Biol Phys 63 : 1546-54, 2005
 
5) Mulhern RK, Merchant TE, Gajjar A, et al : Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5 : 399-408, 2004
PubMed
6) Merchant TE, Hua CH, Shukla H, et al : Proton versus photon radiotherapy for common pediatric brain tumors : comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 51 : 110-7, 2008
PubMed
7) Mizumoto M, Oshiro Y, Yamamoto T, et al : Proton Beam Therapy for Pediatric Brain Tumor. Neurol Med Chir (Tokyo) 57 : 343-55, 2017
PubMed
8) Packer RJ, Gajjar A, Vezina G, et al : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 : 4202-8, 2006
PubMed
9) Lannering B, Rutkowski S, Doz F, et al : Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma : results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30 : 3187-93, 2012
 
10) 日本放射線腫瘍学会編 : 放射線治療計画ガイドライン 2016年版, 金原出版, 東京, 2016
 
11) Eaton BR, Esiashvili N, Kim S, et al : Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy : A Comparison of Disease Control and Overall Survival. Int J Radiat Oncol Biol Phys 94 : 133-8, 2016
PubMed
12) Yock TI, Yeap BY, Ebb DH, et al : Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma : a phase 2 single-arm study. Lancet Oncol 17 : 287-98, 2016
PubMed
13) Howell RM, Giebeler A, Koontz-Raisig W, et al : Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiat Oncol 7 : 116, 2012
 
14) Zhang R, Howell RM, Taddei PJ, et al : A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. Radiother Oncol 113 : 84-8, 2014
PubMed
15) 日本放射線腫瘍学会, 日本小児血液・がん学会編 : 小児・AYA 世代の腫瘍に対する陽子線治療診療ガイドライン 2019年版, 金原出版, 東京, 2019
 
16) Merchant TE, Li C, Xiong X, et al : Conformal radiotherapy after surgery for paediatric ependymoma : a prospective study. Lancet Oncol 10 : 258-66, 2009
PubMed
17) Merchant TE, Bendel AE, Sabin ND, et al : Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. J Clin Oncol 37 : 974-83, 2019
PubMed
18) MacDonald SM, Safai S, Trofimov A, et al : Proton radiotherapy for childhood ependymoma : initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71 : 979-86, 2008
PubMed
19) Journy N, Indelicato DJ, Withrow DR, et al : Patterns of proton therapy use in pediatric cancer management in 2016 : An international survey. Radiother Oncol 132 : 155-61, 2019
PubMed
20) Indelicato DJ, Bradley JA, Rotondo RL, et al : Outcomes following proton therapy for pediatric ependymoma. Acta Oncol 57 : 644-8, 2018
PubMed
21) Mizumoto M, Oshiro Y, Takizawa D, et al : Proton beam therapy for pediatric ependymoma. Pediatr Int 57 : 567-71, 2015
PubMed
22) Alapetite C, Brisse H, Patte C, et al : Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation : the SFOP experience. Neuro-oncology 12 : 1318-25, 2010
PubMed
23) Kanamori M, Kumabe T, Saito R, et al : Optimal treatment strategy for intracranial germ cell tumors : a single institution analysis. J Neurosurg Pediatr 4 : 506-14, 2009
PubMed
24) Park J, Park Y, Lee SU, et al : Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors. Radiat Oncol 10 : 135, 2015
 
25) Greenfield BJ, Jaramillo S, Abboud M, et al : Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy. Clin Transl Radiat Oncol 1 : 9-14, 2016
PubMed
26) Muroi A, Mizumoto M, Ishikawa E, et al : Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma. Childs Nerv Syst 36 : 507-12, 2020
PubMed
27) 日本脳腫瘍学会編, 日本脳神経外科学会監修 : 脳腫瘍診療ガイドライン 2019年版, 金原出版, 東京, 2019
 
28) Graffman S, Haymaker W, Hugosson R, et al : High-energy protons in the postoperative treatment of malignant glioma. Acta Radiol Ther Phys Biol 14 : 443-61, 1975
PubMed
29) Fitzek MM, Thornton AF, Rabinov JD, et al : Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme : results of a phase II prospective trial. J Neurosurg 91 : 251-60, 1999
 
30) Mizumoto M, Tsuboi K, Igaki H, et al : Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 77 : 98-105, 2010
PubMed
31) Matsuda M, Kohzuki H, Ishikawa E, et al : Prognostic analysis of patients who underwent gross total resection of newly diagnosed glioblastoma. J Clin Neurosci 50 : 172-6, 2018
PubMed
P.243 掲載の参考文献
1) Takakura K, Abe H, Tanaka R, et al : Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64 : 53-7, 1986
PubMed
2) Yoshida J, Kajita Y, Wakabayashi T, et al : Long-term follow-up results of 175 patients with malignant glioma : importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127 : 55-9, 1994
PubMed
3) Stupp R, Mason WP, van den Bent MJ, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-96, 2005
PubMed
4) Shibui S, Narita Y, Mizusawa J, et al : Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 71 : 511-21, 2013
PubMed
5) Wakabayashi T, Natsume A, Mizusawa J, et al : JCOG0911 INTEGRA study : a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol 138 : 627-36, 2018
 
6) Gilbert MR, Wang M, Aldape KD, et al : Dose-dense temozolomide for newly diagnosed glioblastoma : a randomized phase III clinical trial. J Clin Oncol 31 : 4085-91, 2013
PubMed
7) Blumenthal DT, Gorlia T, Gilbert MR, et al : Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma : a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 19 : 1119-26, 2017
 
8) Hegi ME, Diserens AC, Gorlia T, et al : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005
PubMed
9) Stupp R, Dietrich PY, Ostermann Kraljevic S, et al : Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 : 1375-82, 2002
PubMed
10) Chheda MG, Drappatz J, Greenberger NJ, et al : Hepatitis B reactivation during glioblastoma treatment with temozolomide : a cautionary note. Neurology 68 : 955-6, 2007
PubMed
11) 日本肝臓学会 : 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン. https://www.jsh.or.jp/files/uploads/R2-HBV%20Ver2.2.pdf
 
12) 有害事象共通用語規準 v5.0 日本語訳 JCOG版 (略称 : CTCAE v5.0-JCOG). http://www.jcog.jp/doctor/tool/CTCAEv5J_20190905_v22_1.pdf
 
13) Brandsma D, Stalpers L, Taal W, et al : Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9 : 453-61, 2008
PubMed
14) Momota H, Narita Y, Miyakita Y, et al : Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 15 : 1445-50, 2013
PubMed
15) Gilbert MR, Dignam JJ, Armstrong TS, et al : A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370 : 699-708, 2014
PubMed
16) Chinot OL, Wick W, Mason W, et al : Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370 : 709-22, 2014
PubMed
17) Friedman HS, Prados MD, Wen PY, et al : Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 : 4733-40, 2009
PubMed
18) Perry JR, Belanger K, Mason WP, et al : Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma : RESCUE study. J Clin Oncol 28 : 2051-7, 2010
PubMed
19) Malmstrom A, Gronberg BH, Marosi C, et al : Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 13 : 916-26, 2012
PubMed
20) Wick W, Platten M, Meisner C, et al : Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly : the NOA-08 randomised, phase 3 trial. Lancet Oncol 13 : 707-15, 2012
PubMed
21) Perry JR, Laperriere N, O'Callaghan CJ, et al : Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376 : 1027-37, 2017
PubMed
22) Buckner JC, Shaw EG, Pugh SL, et al : Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374 : 1344-55, 2016
PubMed
23) Cairncross G, Wang M, Shaw E, et al : Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma : long-term results of RTOG 9402. J Clin Oncol 31 : 337-43, 2013
PubMed
24) van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31 : 344-50, 2013
 
25) van den Bent MJ, Erridge SC, Vogelbaum MA, et al : Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. J Clin Oncol 37 : no. 15_suppl 2000-2000, 2019
 
P.250 掲載の参考文献
1) Matsutani M, Sano K, Takakura K, et al : Primary intracranial germ cell tumors : a clinical analysis of 153 histologically verified cases. J Neurosurg 86 : 446-55, 1997
 
2) Matsutani M, Ushio Y, Abe H, et al : Combined chemotherapy and radiation therapy for central nervous system germ cell tumors : preliminary results of a Phase II study of the Japanese Pediatric Brain Tumor Study Group. Neurosurg Focus 5 : e7, 1998
 
3) Sawamura Y, Ikeda J, Shirato H, et al : Germ cell tumours of the central nervous system : treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer 34 : 104-10, 1998
PubMed
4) Takami H, Fukushima S, Fukuoka K, et al : Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors. J Neurooncol 124 : 23-32, 2015
PubMed
5) Yoshida J, Sugita K, Kobayashi T, et al : Prognosis of intracranial germ cell tumours : effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16). Acta Neurochir (Wien) 120 : 111-7, 1993
PubMed
6) Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 : 9-102, 2017
PubMed
7) Brain Tumor Registry of Japan (2001-2004). Neurologia medico-chirurgica 54 : 1-102, 2014
 
8) Numoto RT, Tanaka J, Yasue M, et al : Clinical, biological and histological considerations on primary intracranial germinomas in the prevalent sites. Noshuyo Byori 10 : 33-41, 1993
PubMed
9) Nakamura H, Takeshima H, Makino K, et al : C-kit expression in germinoma : an immunohistochemistry-based study. J Neurooncol 75 : 163-7, 2005
PubMed
10) Ohta Y, Suzuki T, Tonoike T, et al : Two cases of intracranial germinoma showing a cell arrangement mimicking carcinoma. Diagn Cytopathol 38 : 132-6, 2010
PubMed
11) Murray MJ, Bartels U, Nishikawa R, et al : Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 16 : e470-7, 2015
PubMed
12) Kubota H, Umeda K, Kagehiro K, et al : High-dose chemotherapy with autologous stem cell transplantation spares re-irradiation for recurrent intracranial germinoma. Pediatr Blood Cancer 65 : e27104, 2018
PubMed
P.258 掲載の参考文献
1) Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57 (Suppl 1) : 9-102, 2017
 
2) Grommes C, DeAngelis LM : Primary CNS Lymphoma. Journal of Clinical Oncology 35 : 2410-8, 2017
PubMed
3) Lin CH, Kuo KT, Chuang SS, et al : Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12 : 1152-6, 2006
PubMed
4) Bruno A, Boisselier B, Labreche K, et al : Mutational analysis of primary central nervous system lymphoma. Oncotarget 5 : 5065-75, 2014
PubMed
5) Nakamura T, Tateishi K, Niwa T, et al : Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42 : 279-90, 2016
PubMed
6) Lionakis MS, Dunleavy K, Roschewski M, et al : Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 31 : 833-43 e835, 2017
 
7) Alizadeh AA, Eisen MB, Davis RE, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-11, 2000
PubMed
8) Rosenwald A, Wright G, Chan WC, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 : 1937-47, 2002
PubMed
9) Hans CP, Weisenburger DD, Greiner TC, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-82, 2004
PubMed
10) Seki R, Ohshima K, Fujisaki T, et al : Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100 : 1842-7, 2009
PubMed
11) Wilson WH, Young RM, Schmitz R, et al : Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21 : 922-6, 2015
PubMed
12) Lanfermann H, Heindel W, Schaper J, et al : CT and MR imaging in primary cerebral non-Hodgkin's lymphoma. Acta Radiol 38 : 259-67, 1997
 
13) Sakata A, Okada T, Yamamoto A, et al : Primary central nervous system lymphoma : is absence of intratumoral hemorrhage a characteristic finding on MRI? Radiol Oncol 49 : 128-34, 2015
PubMed
14) Yamasaki F, Takayasu T, Nosaka R, et al : Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis : a characteristic of malignant lymphoma. J Neurosurg 122 : 1370-9, 2015
PubMed
15) Yamasaki F, Kurisu K, Satoh K, et al : Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235 : 985-91, 2005
PubMed
16) Kolakshyapati M, Adhikari RB, Karlowee V, et al : Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma : a novel diagnostic and specific prognostic indicator. J Neurosurg 128 : 667-78, 2018
PubMed
17) Abrey LE, Batchelor TT, Ferreri AJ, et al : Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 : 5034-43, 2005
PubMed
18) Milgrom SA, Yahalom J : The role of radiation therapy in the management of primary central nervous system lymphoma. Leuk Lymphoma 56 : 1197-204, 2015
PubMed
19) Morris PG, Correa DD, Yahalom J, et al : Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma : final results and long-term outcome. J Clin Oncol 31 : 3971-9, 2013
PubMed
20) Herrlinger U, Schafer N, Fimmers R, et al : Early whole brain radiotherapy in primary CNS lymphoma : negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143 : 1815-21, 2017
 
21) Alnahhas I, Jawish M, Alsawas M, et al : Autologous Stem-Cell Transplantation for Primary Central Nervous System Lymphoma : Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 19 : e129-e41, 2019
 
22) Goldman ID, Matherly LH : The cellular pharmacology of methotrexate. Pharmacol Ther 28 : 77-102, 1985
PubMed
23) Brody J, Kohrt H, Marabelle A, Levy R : Active and passive immunotherapy for lymphoma : proving principles and improving results. J Clin Oncol 29 : 1864-75, 2011
PubMed
24) Bromberg JEC, van der Meulen M, Doorduijn JK : The Role of Rituximab in Primary Central Nervous System Lymphoma. Curr Oncol Rep 22 : 78, 2020
PubMed
25) Roila F, Molassiotis A, Herrstedt J, et al : 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27 (suppl 5) : v119-v33, 2016
 
26) Lopez JA, Nassif E, Vannicola P, et al : Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 3 : 119-24, 1985
PubMed
27) Sioka C, Kyritsis AP : Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63 : 761-7, 2009
PubMed
28) Chapuy B, Roemer MG, Stewart C, et al : Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127 : 869-81, 2016
PubMed
29) Wu J, Liu C, Tsui ST, et al : Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9 : 80, 2016
PubMed
30) Owen C, Berinstein NL, Christofides A, et al : Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol 26 : e233-e40, 2019
PubMed
31) Woyach JA, Furman RR, Liu TM, et al : Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370 : 2286-94, 2014
PubMed
32) Kozaki R, Vogler M, Walter HS, et al : Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers (Basel) 10, 2018
 
33) Narita Y, Nagane M, Mishima K, et al : Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma. Neuro Oncol 2020 Jun 25
 
P.265 掲載の参考文献
1) Kayama T, Sato S, Shibui S, et al ; Japan Clinical Oncology Group : Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504) : A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol 36 : 3282-89, 2018
 
2) Yamamoto M, Serizawa T, Saeki N, et al : Stereotactic radiosurgery for patients with multiple brain metastases (JGLK0901) : a multi-institutional prospective observational study. Lancet Oncol 15 : 387-95, 2014
PubMed
3) Iwadate Y, Fukuda K, Matsutani T, et al : Intrinsic protective mechanisms of neuron-glia network against glioma invasion. J Clin Neurosci 26 : 19-25, 2016
 
4) Iwadate Y : Epithelial-mesenchymal transition in glioblastoma progression. Oncol Lett 11 : 1615-20, 2016
PubMed
5) Crino L, Ahn MJ, De Marinis F, et al : Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small cell lung cancer previously treated with chemotherapy and crizotinib : results from ASCEND-2. J Clin Oncol 34 : 2866-73, 2016
PubMed
6) Iuchi T, Shingyoji M, Sakaida T, et al : Phase II trial of gefitinib alone without radiation therapy for Japanease patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82 : 282-7, 2013
 
7) Reungwetwattana T, Nakagawa K, Cho BC, et al : CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small cell lung cancer. J Clin Oncol 36 : 3290-7, 2018
 
8) Bachelot T, Romieu G, Campone M, et al : Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE) : a single-group phase 2 study. Lancet Oncol 14 : 64-71, 2013
PubMed
9) Davies MA, Saiag P, Robert C, et al : Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB) : a multicenter, multicohort, open-label, phase 2 trial. Lancet Oncol 18 : 863-73, 2017
 
10) Kim R, Keam B, Kim S, et al : Difference in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients : therapeutic implications for immune checkpoint inhibitors. BMC Cancer 19 : 19, 2019
 
11) Weichselbaum RR, Liang H, Deng Liufu, et al : Radiotherapy and immunotherapy : a beneficial liaison? Nat Rev Clin Oncol 6 : 365-79, 2017
PubMed
12) Demaria S, Golden EB, Formenti SC : Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1 : 1325-32, 2015
PubMed
13) Guavain C, Vauleon E, Chouaid C, et al : Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer 116 : 62-6, 2018
 
14) Crino L, Bronte G, Bidoli P, et al : Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 129 : 35-40, 2019
PubMed
15) Goldberg SB, Gettinger SN, Mahajan A, et al : Pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases : early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17 : 76-83, 2016
 
16) Long GV, Atkinson V, Lo S, et al : Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases : a multicentre randomised phase 2 study. Lancet Oncol 19 : 672-81, 2018
 
17) Tawbi H, Forsyth PA, Algazi A, et al : Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Eng J Med 379 : 722-30, 2018
 
18) Spigel DR, Chaft JE, Gettinger S, et al : FIR : efficacy, safty, and biomarker analysis of a phase II open-label study of atezolizmab in PD-L1-selected patients with NSCLC. J Thorac Oncol 13 : 1733-42, 2018
 
19) Rittmeyer A, Barlesi F, Waterkamp D, et al : Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK) : a phase 3, open-label, multicenter randomized control trial. Lancet 389 : 255-65, 2017
 
20) Lamier CM, Hughes R, Ahmed T, et al : Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neuro-Oncol Prac 6 : 402-9, 2019
 
P.273 掲載の参考文献
1) Kirson D, Gurvich Z, Schneiderman R, et al : Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Res 64 : 3288-95, 2004
 
2) Lee SX, Wong ET, Swanson KD : CB-013. Mitosis Interference of cancer cells by NOVOTTF-100 A causes decreased cellular viability. Neuro Oncol 14 (suppl_6) : vi7-vi20, 2012
 
3) Kirson ED, Dbaly V, Tovarys F, et al : Alternating Electric Fields Arrest Cell Proliferation in Animal Tumor Models and Human Brain Tumors. Proc Natl Acad Sci USA 104 : 10151-7, 2007
 
4) Gutin PH, Wong ET : Noninvasive Application of Alternating Electric Fields in Glioblastoma : A Fourth Cancer Treatment Modality. Am Soc Clin Oncol Educ Book 2012 : 126-31, 2012
PubMed
5) Stupp R, Hegi ME, Idbaih A, et al : Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM) : fInal results of a randomized, multicenter, phase III trial. In : Program and abstracts of the 2017 Annual Meeting of the American Association for Cancer Research ; April 1-5, 2017 ; Washington, DC. Abstract LBA AACR CT007.
 
6) Stupp R, Hegi ME, Idbaih A, et al : Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM) : final results of a randomized, multicenter, phase III trial. Presented at : 2017 Annual Meeting of the American Association for Cancer Research ; April 1-5, 2017 ; Washington, DC. Oral presentation LBA AACR CT007
 
7) Stupp R, Wong ET, Kanner AA, et al : NovoTTF-100 A Versus Physician's Choice Chemotherapy in Recurrent Glioblastoma : A Randomised Phase III Trial of a Novel Treatment Modality. Eur J cancer 48 : 2192-202, 2012
PubMed
8) Stupp R, Taillibert S, Kanner AA, et al : Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma : a randomized clinical trial. JAMA 314 : 2535-43, 2015
PubMed
9) Lacouture ME, Davis ME, Elzinga G, et al : Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100 A System, a Novel Anti-Mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma. Semin Oncol 41 (Suppl 4) : S1-14, 2014
 
P.280 掲載の参考文献
1) Glioma Meta-analysis Trialists (GMT) Group (Stewart LA) : Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-8, 2002
 
2) Stupp R, Mason WP, van den Bent MJ, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-96, 2005.
PubMed
3) Silbergeld DL, Chicoine MR : Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86 : 525-31, 1997
 
4) Tsuboi K, Saijo K, Ishikawa E, et al : Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 9 : 3294-302, 2003
PubMed
5) Ishikawa E, Tsuboi K, Saijo K, et al : Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24 (3b) : 1861-71, 2004
PubMed
6) 山中龍也 : 脳腫瘍の免疫療法. 樹状細胞ワクチン. V 脳腫瘍の治療. 新時代の脳腫瘍学. 日本臨牀 68 (suppl 10) : 520-5, 2010
 
7) Yu JS, Wheeler CJ, Zeltzer PM, et al : Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 : 842-7, 2001
PubMed
8) Yamanaka R : Novel immunotherapeutic approaches to glioma. Curr Opin Mol Ther 8 : 46-51, 2006. Review
PubMed
9) Weller M, Butowski N, Tran DD, et al : ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV) : a randomised, double-blind, international phase 3 trial. Lancet Oncol 18 : 1373-85, 2017
 
10) 寺崎瑞彦 : ワクチン療法. XII 特論. 脳腫瘍学-基礎研究と臨床研究の進歩-. 日本臨牀 74 (suppl 7) : 769-775, 2016
 
11) Narita Y, Arakawa Y, Yamasaki F, et al : A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol 21 : 348-59, 2019
PubMed
12) Tsuboi A, Hashimoto N, Fujiki F, et al : A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother 68 : 331-40, 2019
 
13) Hilf N, Kuttruff-Coqui S, Frenzel K, et al : Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565 : 240-5, 2019
PubMed
14) Young JS, Dayani F, Morshed RA, et al : Immunotherapy for high grade gliomas : A clinical update and practical considerations for neurosurgeons. World Neurosurg 2019 Jan 21. [Epub ahead of print]
 
15) Ohno T : Autologous Cancer Vaccine : A Novel Formulation. Microbiol Immunol 47 : 255-63, 2003
PubMed
16) Akasaki Y, Kikuchi T, Homma S, et al : Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. Cancer Immunol Immunother 65 : 1499-1509, 2016
PubMed
17) Kim C, Matsumura M, Saijo K, et al : In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 47 : 90-6, 1998
PubMed
18) Liu SQ, Saijo K, Todoroki T, et al : Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Medicine 1 : 267-71, 1995
PubMed
19) Liu SQ, Shiraiwa H, Kawai K, et al : Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nature Med 2 : 1283-3, 1996
PubMed
20) Ishikawa E, Tsuboi K, Takano S, et al : Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of an intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model. Cancer Sci 95 : 98-103, 2004
 
21) Ishikawa E, Tsuboi K, Yamamoto T, et al : A clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 98 : 1226-33, 2007
 
22) Muragaki Y, Maruyama T, Iseki H, et al : Phase I/IIa Trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for initially-diagnosed glioblastoma. J Neuro Surg 115 : 248-55, 2011
 
23) Ishikawa E, Muragaki Y, Yamamoto T, et al : Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg 4 : 1-11, 2014
PubMed
24) Muragaki Y, Maruyama T, Ishikawa E, et al : Multicenter randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly-diagnosed glioblastomas. Neuro-Oncology 19 : suppl 6, vi315, 2017
 
25) Berghoff AS, Kiesel B, Widhalm G, et al : Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17 : 1064-75, 2015
PubMed
26) Schreiber RD, Old LJ, Smyth MJ : Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion. Science 331 : 1565-70, 2011
PubMed
27) Liu Y, Carlsson R, Ambjorn M, et al : PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci 33 : 14231-45, 2013
PubMed
28) Nduom EK, Wei J, Yaghi NK, et al : PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18 : 195-205, 2016
PubMed
29) 宮崎翼 : 初発・再発膠芽腫組織を使用した腫瘍微小環境の変化の解析とテモゾロミド耐性TS細胞に対する抗PD-L1抗体+M2マクロファージ阻害剤併用療法の検討. 筑波大学博士 (医学) 論文, 2019
 
30) Miyazaki T, Ishikawa E, Matsuda M, et al : Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol 133 : 277-85, 2017
PubMed
31) Mandai M, Hamanishi J, Abiko K, et al : Dual faces of IFNγ in cancer progression : A role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res 22 : 2329-34, 2016
 
32) Terawaki S, Chikuma S, Shibayama S, et al : IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186 : 2772-9, 2011
 
33) Omuro A, Vlahovic G, Lim M, et al : Nivolumab with or without ipilimumab in patients with recurrent glioblastoma : results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 20 : 674-86, 2018
PubMed
34) Cloughesy TF, Mochizuki AY, Orpilla JR, et al : Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25 : 477-86, 2019
PubMed
35) Zhao J, Chen AX, Gartrell RD, et al : Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 25 : 462-9, 2019
 
36) Duraiswamy J, Freeman GJ, Coukos G : Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors-response. Cancer Res 74 : 633-4, 2014
PubMed
37) Karyampudi L, Lamichhane P, Scheid AD, et al : Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 74 : 2974-85, 2014
PubMed
38) Miyoshi T, Kataoka T, Asahi A, et al : A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody. Clin Case Rep 4 : 687-91, 2016
PubMed
39) Miyazaki T, Ishikawa E, Matsuda M, et al : Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol 2020 Jan 24. [Epub ahead of print]
 
40) Kaneda MM, Messer KS, Ralainirina N, et al : PI3Kγ is a molecular switch that controls immune suppression. Nature 539 : 437-42, 2016
 
41) De Henau O, Rausch M, Winkler D, et al : Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539 : 443-7, 2016
 
42) Miyazaki T, Ishikawa E, Sugii N, et al : Therapeutic strategies for overcoming immunotherapy resistance mediated by immunosuppressive factors of the glioblastoma microenvironment. Cancers (Basel) 12 : E1960, 2020
 

書評

最近チェックした商品履歴

Loading...